Therapeutic opportunities of small interfering RNA

Fundamental and Clinical Pharmacology

Volumn 23, Issue 4, 2009, Pages 367-386

  Goyal, Bhoomika R ^a   Patel, Mayur M ^a   Soni, Mithil K ^a   Bhadada, Shraddha V ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Cancer; Cardiovascular diseases; CNS disorders; Delivery; SiRNA

Indexed keywords

DOUBLE STRANDED RNA; MESSENGER RNA; NUCLEASE; SHORT HAIRPIN RNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA;

ADDICTION; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATION TRANSPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; DEVELOPMENTAL DISORDER; DRUG SPECIFICITY; ENZYME BINDING; GENE TARGETING; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUNTINGTON CHOREA; HYPERTENSION; INFECTION; KENNEDY DISEASE; LIVER DISEASE; MACHADO JOSEPH DISEASE; MUSCULAR DYSTROPHY; MYOCARDITIS; NEOPLASM; NONVIRAL GENE DELIVERY SYSTEM; NUCLEIC ACID AMPLIFICATION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; RNA INTERFERENCE; RNA SYNTHESIS; RNA TRANSPORT; SIGNAL TRANSDUCTION; SPINAL MUSCULAR ATROPHY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING;

EID: 68749087654     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00694.x     Document Type: Review

References (178)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391 806 811. (Pubitemid 28099681)
2. Ngo H., Tschudi C., Gull K., Ullu E. Double stranded RNA induced mRNA degradation in Trypanosoma brucei. Proc. Natl Acad. Sci. USA (1998) 95 14687 14692.
3. Kennerdell J.R., Carthew R.W. Use of dsRNA mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell (1998) 95 1017 1026.
4. Sanchez A.A., Newmark P.A. Double stranded RNA specifically disrupts gene expression during planarian regeneration. Proc. Natl Acad. Sci. USA (1999) 96 5049 5054.
5. Oril H., Mochii M., Watnabe K. A simple ''soaking method'' for RNA interference in planarian Dugesia japonica. Dev. Genes. Evol. (2003) 213 138 141.
6. Lohmann J.U., Endl I., Bosch T.C. Silencing of developmental genes in Hydra. Dev. Biol. (1999) 1 211 214.
7. Waterhouse P.M., Helliwell C.A. Exploring plant genomes by RNA-induced gene silencing. Nat. Rev. Genet. (2003) 4 29 38.
8. Wargelius A., Ellingsen S., Fjose A. Double stranded RNA induces specific developmental defects in zebrafish embryo. Biochem. Biophys. Res. Commun. (1999) 263 156 161.
9. Wianny F., Zernicka G.M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat. Cell Biol. (2000) 2 70 75.
10. Sorensen D.R., Leirdal M., Siod M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. (2003) 327 761 766.
11. Stein P., Svoboda P., Schultz R.M. Transgenic RNAi in mouse oocytes: a simple and fast approach to study gene function. Dev. Biol. (2003) 256 187 193.
12. McManus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. (2002) 3 737 747.
13. Shi Y. Mammalian RNAi for the masses. Trends Genet. (2003) 19 9 12.
14. Yin J.Q., Gao J., Shao R., Tian W.N., Wang J., Wan Y. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J. Exp. Ther. Oncol. (2003) 3 194 204.
15. Drosett Y., Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug. Discov. (2004) 3 318 329.
16. de Francesco R., Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature (2005) 436 953 960.
17. Liu T.G., Yin Q., Shang B.Y. et al. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther. (2004) 11 748 756.
18. Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol. (2006) 124 12 25. (Pubitemid 43816129)
19. Bass B.L. Double-stranded RNA as a template for gene silencing. Cell (2000) 101 235 238.
20. Zamore P., Tuschl T., Sharp P., Bartel D. RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals. Cell (2000) 101 25 33.
21. Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 409 363 366.
22. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15 188 200. (Pubitemid 32107664)
23. Depicker A., Van Montagu M. Post-transcriptional gene silencing in plants. Curr. Opin. Cell Biol. (1997) 9 373 382.
24. Lipardi C., Wei Q., Paterrson B.M. RNAi as random degradation PCR: siRNA primers convert mRNA into dsRNA that are degraded to generate new siRNAs. Cell (2001) 107 297 307.
25. Sijen T., Fleenor J., Simmer F. et al. On the role of RNA amplification in dsRNA-triggered gene silencing. Cell (2001) 107 465 476.
26. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270 1628 1644.
27. Verma S., Jager S., Thum O., Famulok M. Functional tuning of nucleic acids by chemical modifications: tailored oligonucleotides as drugs, devices, and diagnostics. Chem. Rec. (2003) 3 51 60.
28. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. (2004) 8 570 579.
29. Hall A.H., Wan J., Shaughnessy E.E., Ramsay Shaw B., Alexander K.A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. (2004) 32 5991 6000.
30. Braasch D.A., Jensen S., Liu Y. et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (2003) 42 7967 7975.
31. Czauderna F., Fechtner M., Dames S. et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. (2003) 31 2705 2716.
32. Harborth J., Elbashir S.M., Vandenburgh K. et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. (2003) 13 83 105.
33. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA (2004) 10 766 771.
34. Prakash T.P., Allerson C.R., Dande P. et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. (2005) 48 4247 4253.
35. Hoshika S., Minakawa N., Kamiya H., Harashima H., Matsuda A. RNA interference induced by siRNAs modified with 4′- thioribonucleosides in cultured mammalian cells. FEBS Lett. (2005) 579 3115 3118.
36. Liao H., Wang J.H. Biomembrane-permeable and ribonuclease resistant siRNA with enhanced activity. Oligonucleotides (2005) 15 196 205.
37. Muratovska A., Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. (2004) 558 63 68.
38. Soutschek J., Akinc A., Bramlage B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432 173 178.
39. Carstea E.D., Hough S., Wiederholt K., Welch P.J. State-of the- art modified RNAi compounds for therapeutics. IDrugs (2005) 8 642 647.
40. Judge A.D., Bola G., Lee A.C.H., MacLachlan I. Design of non-inflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. (2006) 13 494 505.
41. Kimchi-Sarfaty C., Brittain S., Garfield S., Caplen N.J., Tang Q., Gottesman M.M. Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum. Gene Ther. (2005) 16 1110 1115.
42. de Jonge J., Holtrop M., Wilschut J., Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther. (2006) 13 400 411.
43. Uprichard S.L., Boyd B., Althage A., Chisari F.V. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. U S A (2005) 102 773 778.
44. Uchida H., Tanaka T., Sasaki K. et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol. Ther. (2004) 10 162 171.
45. Dittgen T., Nimmerjahn A., Komai S. et al. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc. Natl. Acad. Sci. USA (2004) 101 18206 18211.
46. Godfrey A., Anderson J., Papanastasiou A., Takeuchi Y., Bosho C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood (2005) 105 2510 2518.
47. Ralph G.S., Radcliffe P.A., Day D.M. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. (2005) 11 429 433.
48. Raoul C., Abbas-Terki T., Bensadoun J.C. et al. Lentiviral mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. (2005) 11 423 428.
49. Bot I., Guo J., Van Eck M. et al. Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo. Blood (2005) 106 1147 1153.
50. Jia W., Zhou Q. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. Curr. Gene. Thera. (2005) 5 133 142.
51. Palmer D.J., Ng P. Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. (2005) 16 1 16.
52. Wolkowicz R., Nolan G.P. Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Ther. (2005) 12 467 476.
53. Yi Y., Hahm S.H., Lee K.H. Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther. (2005) 5 25 35.
54. Wurdinger T., Verheije M.H., Broen K. et al. Soluble receptor mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. J. Virol. (2005) 79 15314 15322.
55. Xiong Z., Cheng Z., Zhang X. et al. Imaging chemically modified adenovirus for targeting tumors expressing integrin {alpha}v{beta}3 in living mice with mutant herpes simplex virus type 1 thymidine Kinase PET reporter gene. J. Nucl. Med. (2006) 47 130 139.
56. Kappes J.C., Wu X. Safety considerations in vector development. Somat. Cell Mol. Genet. (2001) 26 175 191.
57. Monahan P.E., Jooss K., Sands M.S. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin. Drug Saf 2002) 1 79 91.
58. Guo S., Tschammer N., Mohammed S., Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29motor pRNA. Hum. Gene Ther. (2005) 16 1097 1109.
59. Luo M.C., Zhang D.Q., Ma S.W. et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol. Pain (2005) 1 29 36.
60. Pal A., Ahmad A., Khan S. et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Onc. (2005) 26 1087 1091.
61. Omidi Y., Barar J., Akhtar S. Toxicogenomics of cationic lipid based vectors for gene therapy: impact of microarray technology. Curr. Drug Deliv. (2005) 2 429 441.
62. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. (2005) 348 1079 1090.
63. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. (2005) 12 461 466.
64. Minakuchi Y., Takeshita F., Kosaka N. et al. Atelocollagen mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. (2004) 32 e109.
65. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. (2004) 64 3365 3370.
66. Takeshita F., Minakuchi Y., Nagahara S. et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U S A (2005) 102 12177 12182.
67. Song E., Zhu P., Lee S.K. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotech. (2005) 23 709 717.
68. Pirollo K.F., Zon G., Rait A. et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. (2006) 17 117 124.
69. Schifielers R.M., Ansari A., Xu J. et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. (2004) 32 e149.
70. Kim B., Tang Q., Biswas P.S. et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. (2004) 165 2177 2185.
71. Kannel W.B. Left ventricular hypertrophy as a risk factor: the Framingham experience. J. Hypertens. (1991) 9 (Suppl) S3.
72. Higachi J., Baba S., Katsuya T. et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men. The Suita Study. Circulation (2000) 101 2060 2065.
73. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet (2000) 355 637 645.
74. Gurley S.B., Le T.H., Coffman T.M. Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease. Cold Spring Harb. Symp. Quant. Biol. (2002) 67 451 457.
75. Vazquez J., Correa de Adjounian M.F., Sumners C. et al. Selective silencing of angiotensin receptor subtype 1a (AT1aR) by RNA interference. Hypertension (2005) 45 115 119.
76. Chen Y., Currie R.W. Small interfering RNA knocks down heat shock factor-1 (HSF-1) and exacerbates pro-inflammatory activation of NF-kappaB and AP-1 in vascular smooth muscle cells. Cardiovasc. Res. (2006) 69 66 75.
77. Sward K., Mita M., Wilson D.P., Deng J.T., Susnjar M., Walsh M.P. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr. Hypertens. Rep. (2003) 5 66 72.
78. Bi D., Nishimura J., Niiro N., Hirano K., Kanaide H. Contractile properties of the cultured vascular smooth muscle cells. The crucial role played by RhoA in the regulation of contractility. Circ. Res. (2005) 96 890 897.
79. Hansson S.M., Bernstein E., Beach D., Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 404 293 296.
80. Kobashi C., Urakaze M., Kishida M. et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. (2005) 97 1245 1252.
81. Collins T., Cybulsky M.I. NF-kappa B: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. (2001) 107 255 264.
82. Dwarakanath R.S., Sahar S., Reddy M.A., Castanotto D., Rossi J.J., Natarajan R. Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappaB). J. Mol. Cell. Cardiol. (2004) 36 585 595.
83. Bennett M.R. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. (1999) 41 361 368.
84. Blaschke F., Bruemmer D., Yin F. et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation (2004) 110 579 587.
85. Martins L.M., Iaccarino I., Tenev T. et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol. Chem. (2002) 277 439 444.
86. Liu X., Li T., Sun S., Xu F., Wang Y. Role of myofibrillogenesis regulator-1 in myocardial hypertrophy. Am. J. Physiol. Heart. Circ. Physiol. (2006) 290 H279 H285.
87. Si X., Rahmarni M., Yuan J., Lou H. Detection of cardiac signaling in the injured and hypertrophied heart. Methods Mol. Med. (2005) 112 291 303.
88. Pedram A., Razandi M., Aitkenhead M., Levin E.R. Estrogen inhibits cardiomyocyte hypertrophy in vitro: Antagonism of calcineurin- related hypertrophy through induction of MCIP1. J. Biol. Chem. (2005) 280 26339 26348.
89. Liu P., Martino T., Opavsky M.A., Penninger J. Viral myocarditis: balance between viral infection and immune response. Can. J. Cardiol. (1996) 12 935 943.
90. Yang D., Yu J., Luo Z. et al. Viral myocarditis identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart. Circ. Res. (1999) 84 704 712.
91. Schubert S., Grunert H.P., Zeichhardt H., Werk D., Erdmann V.A., Kurreck J. Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J. Mol. Biol. (2005) 346 457 465.
92. Yuan J., Cheung P.K., Zhang H.M., Chau D., Yang D. Inhibition of coxsackie virus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J. Virol. (2005) 79 2151 2159.
93. Hobai I.A., O'Rourke B. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation (2001) 103 1577 1584.
94. 2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J. Mol. Cell. Cardiol. (2004) 37 691 698.
95. Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul. Disord. (2002) 12 926 929.
96. Grisoni K., Martin E., Gieseler K., Mariol M.C., Segalat L. Genetic evidence for a dystrophin-glycoprotein complex (DGC) in Caenorhabditis elegans. Gene (2002) 294 77 86.
97. Mariol M.C., Segalat L. Muscular degeneration in the absence of dystrophin is a calcium-dependent process. Curr. Biol. (2001) 11 1691 1694.
98. Goldman R.D., Gruenbaum Y., Moir R.D., Shumaker D.K., Spann T.P. Nuclear lamins: building blocks of nuclear architecture. Genes Dev. (2002) 16 533 547.
99. Gruenbaum Y., Lee K.K., Liu J., Cohen M., Wilson K.L. The expression, lamin-dependent localization and RNAi depletion phenotype for emerin in C. elegans. J. Cell Sci. (2002) 115 (Pt 5 923 929.
100. Liu J., Lee K.K., Segura-Totten M., Neufeld E., Wilson K.L., Gruenbaum Y. MAN1 and emerin have overlapping function(s) essential for chromosome segregation and cell division in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA (2003) 100 4598 4603.
101. Miguel-Aliaga I., Culetto E., Walker D.S., Baylis H.A., Sattelle D.B., Davies K.E. The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum. Mol. Genet. (1999) 8 2133 2143.
102. Chan Y.B., Miguel-Aliaga I., Franks C. et al. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum. Mol. Genet. (2003) 12 1367 1376.
103. Ilangovan R., Marshall W.L., Hua Y., Zhou J. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. J. Biol. Chem. (2003) 278 30993 30999.
104. Link C.D., Taft A., Kapulkin V. et al. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging (2003) 24 397 413.
105. Yagi Y., Tomita S., Nakamura M., Suzuki T. Overexpression of human amyloid precursor protein in Drosophila. Mol. Cell. Biol. Res. Commun. (2000) 4 43 49.
106. Greeve I., Kretzschmar D., Tschape J.A. et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. (2004) 24 3899 3906.
107. Iijima K., Liu H.P., Chiang A.S., Hearn S.A., Konsolaki M., Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. U S A (2004) 101 6623 6628.
108. Takasugi N., Takahashi Y., Morohashi Y., Tomita T., Iwatsubo T. The mechanism of gamma-secretase activities through high molecular weight complex formation of presenilins is conserved in Drosophila melanogaster and mammals. J. Biol. Chem. (2002) 277 50198 50205.
109. Francis R., McGrath G., Zhang J. et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of beta APP and presenilin protein accumulation. Dev. Cell. (2002) 3 85 97.
110. Asai M., Hattori C., Szabo B. et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem. Biophys. Res. Commun. (2003) 301 231 235.
111. Kao S.C., Krichevsky A.M., Kosik K.S., Tsai L.H. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. (2004) 279 1942 1949.
112. Gusella J.F., Wexler N.S., Conneally P.M. et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature (1983) 306 234 238.
113. Beal M.F., Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. (2004) 5 373 384.
114. Cummings C.J., Zoghbi H.Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet. (2000) 9 909 916.
115. Lieberman A.P., Fischbeck K.H. Triplet repeat expansion in neuromuscular disease. Muscle Nerve (2000) 23 843 850.
116. Nollen E.A., Garcia S.M., van Haaften G. et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc. Natl. Acad. Sci. U S A (2004) 101 6403 6408.
117. Caplen N.J., Taylor J.P., Statham V.S., Tanaka F., Fire A., Morgan R.A. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum. Mol. Genet. (2002) 11 175 184.
118. Yang Y., Nishimura I., Imai Y., Takahashi R., Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron (2003) 37 911 924.
119. Hommel J.D., Sears R.M., Georgescu D., Simmons D.L., DiLeone R.J. Local gene knockdown in the brain using viral-mediated RNA interference. Nat. Med. (2003) 9 1539 1544.
120. Miller V.M., Xia H., Marrs G.L. et al. Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA (2003) 100 7195 7200.
121. Gaspar C., Lopes-Cendes I., Hayes S. et al. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am. J. Hum. Genet. (2001) 68 523 528.
122. Hemmings-Mieszczak M., Dorn G., Natt F.J., Hall J., Wishart W.L. Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant rat P2X3 receptor. Nucleic Acids Res. (2003) 31 2117 2126.
123. Dorn G., Patel S., Wotherspoon G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. (2004) 32 e49.
124. Zhang W.B., Zhang Z., Ni Y.X., Wu Y.L., Pei G. A novel function of Goá: Mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells. J. Neurochem. (2003) 86 1213 1222.
125. Grünweller A., Wyszko E., Bieber B., Jahnel R., Erdmann V.A., Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. (2003) 31 3185 3193.
126. Bai J., Ramos R.L., Ackman J.B., Thomas A.M., Lee R.V., LoTurco J.J. RNAi reveals doublecortin is required for radial migration in rat neocortex. Nat. Neurosci. (2003) 6 1277 1283.
127. Larsson A., Engel J.A. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci. Biobehav. Rev. (2004) 27 713 720.
128. Dzitoyeva S., Dimitrijevic N., Manev H. Gamma-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: adult RNA interference and pharmacological evidence. Proc. Natl. Acad. Sci. USA (2003) 100 5485 5490.
129. Gottschalk P.C., Jacobsen L.K., Kosten T.R. Current concepts in pharmacotherapy of substance abuse. Curr. Psychiatry Rep. (1999) 1 172 178.
130. Waggoner L.E., Dickinson K.A., Poole D.S., Tabuse Y., Miwa J., Schafer W.R. Long-term nicotine adaptation in Caenorhabditis elegans involves PKC-dependent changes in nicotinic receptor abundance. J. Neurosci. (2000) 20 8802 8811.
131. Kittler R., Buchholz F. RNA interference: gene silencing in the fast lane. Semin. Cancer Biol. (2003) 13 259 265.
132. Lu P.Y., Xie F.Y., Woodle M.C. siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther. (2003) 5 225 234.
133. Wall N.R., Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet (2003) 362 1401 1403.
134. Buchele T. Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide) - review of preclinical and clinical results. Onkologie (2003) 26 (Suppl. 7) 60 69.
135. Wilda M., Fuchs U., Wossmann W., Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene (2002) 21 5716 5724.
136. Scherr M., Battmer K., Winkler T., Heidenreich O., Ganser A., Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood (2003) 101 1566 1569.
137. Heidenreich C., Krauter J., Riehle H. et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood (2003) 101 3157 3163.
138. Aoki Y., Cioca D., Oidaira H., Kamiya J., Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin. Exp. Pharmacol. Physiol. (2003) 30 96 102.
139. Cioca D.P., Aoki Y., Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. (2003) 10 125 133.
140. Siegmund D., Hadwiger P., Pfizenmaier K., Vornlocher H.P., Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL induced apoptosis. Mol. Med. (2002) 8 725 732.
141. Zhang D., Li F., Weidner D., Mnjoyan Z.H., Fujise K. Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone. J. Biol. Chem. (2002) 277 37430 37438.
142. Nagashima K., Endo A., Ogita H. et al. Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. Mol. Biol. Cell (2002) 13 4231 4242.
143. Tsuneoka M., Koda Y., Soejima M., Teye K., Kimura H. A novel myc target gene, mina53, that is involved in cell proliferation. J. Biol. Chem. (2002) 277 35450 35459.
144. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296 550 553.
145. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2 243 247.
146. Bruno S., Ghiotto F., Fais F. et al. The PML gene is not involved in the regulation of MHC class I expression in human cell lines. Blood (2003) 101 3514 3519.
147. Jiang M., Milner J. Selective silencing of viral gene expression in HPV-positive humancervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene (2002) 21 6041 6048.
148. Peng Y., Zhang Q., Nagasawa H., Okayasu R., Liber H.L., Bedford J.S. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res. (2002) 62 6400 6404.
149. Crans-Vargas H.N., Landaw E.M., Bhatia S., Sandusky G., Moore T.B., Sakamoto K.M. Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood (2002) 99 2617 2619.
150. Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature (2004) 431 371 378.
151. Jacque J.M., Triques K., Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature (2002) 418 435 438.
152. Lee N.S., Dohjima T., Bauer G. et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. (2002) 20 500 505.
153. Novina C.D., Murray M.F., Dykxhoorn D.M. et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. (2002) 8 681 686.
154. Boden D., Pusch O., Lee F., Tucker L., Ramratnam B. Human immunodeficiency virus type-1 escape from RNA interference. J. Virol. (2003) 77 11531 11535.
155. Klatzmann D., Champagne E., Chamaret S. et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1984) 312 767 768.
156. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 47 333 348.
157. Liu R., Paxton W.A., Choe S. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86 367 377.
158. Samson M., Libert F., Doranz B.J. et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382 722 725.
159. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl Acad. Sci. USA (2003) 100 183 188.
160. Surabhi R.M., Gaynor R.B. RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol. (2002) 76 12963 12973.
161. Silva J.M., Hammond S.M., Hannon G.J. RNA interference: a promising approach to antiviral therapy? Trends Mol. Med. (2002) 8 505 508.
162. Tan Y.T., Tillett D.J., McKay I.A. Molecular strategies for overcoming antibiotic resistance in bacteria. Mol. Med. Today (2000) 6 309 314.
163. Franz D.R., Zajtchuk R. Biological terrorism: understanding the threat, preparation and medical response. Dis. Monit. (2002) 48 493 564.
164. Dector M.A., Romero P., López S., Arias C.F. Rotavirus gene silencing by small interfering RNAs. EMBO Rep. (2002) 3 1175 1180.
165. Ge Q., McManus M.T., Nguyen T. et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl Acad. Sci. USA (2003) 100 2718 2723.
166. Malhotra P., Dasaradhi P.V., Kumar A. et al. Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Mol. Microbiol. (2002) 45 1245 1254.
167. Liu H., Cottrell T.R., Pierini L.M., Goldman W.E., Doering T.L. RNA interference in the pathogenic fungus Cryptococcus neoformans. Genetics (2002) 160 463 470.
168. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., Kay M.A. RNA interference in adult mice. Nature (2002) 418 38 39.
169. Lohmann V., Körner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285 110 113.
170. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science (2000) 290 1972 1974.
171. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. (2001) 75 1252 1264. (Pubitemid 32094684)
172. Ikeda M., Yi M., Li K., Lemon S.M. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J. Virol. (2002) 76 2997 3006.
173. Wilson J.A., Jayasena S., Khvorova A. et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl Acad. Sci. USA (2003) 100 2783 2788.
174. Randall G., Grakoui A., Rice C.M. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl Acad. Sci. USA (2003) 100 235 240.
175. Zender L., Hutker S., Liedtke C. et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl Acad. Sci. USA (2003) 100 7797 7802.
176. Chalupsky K., Cai H. Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA (2005) 102 9056 9061.
177. Li Y., Takemura G., Kosai K. et al. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ. Res. (2004) 95 627 636.
178. Hamar P., Song E., Kokeny G., Chen A., Ouyang N., Lieberman J. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA (2004) 101 14883 14888.